- Conditions
- Giant Cell Arteritis
- Interventions
- mavrilimumab, placebo, prednisone
- Combination Product · Drug
- Lead sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Sarasota, Florida • Tampa, Florida • Atlanta, Georgia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arthritis, Rheumatoid
- Interventions
- KPL-404, Placebo
- Drug
- Lead sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 19
- States / cities
- Apple Valley, California • Covina, California • Upland, California + 15 more
- Conditions
- Healthy Volunteers
- Interventions
- KPL-404, Matching Placebo
- Drug · Other
- Lead sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- COVID-19, Sars-CoV2, Pneumonia
- Interventions
- Mavrilimumab, Placebos
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Interventions
- Mavrilimumab, Placebos
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Weston, Florida • Cleveland, Ohio
- Conditions
- Recurrent Pericarditis
- Interventions
- Rilonacept, Placebo
- Drug
- Lead sponsor
- Kiniksa Pharmaceuticals (UK), Ltd.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 9 more
- Conditions
- Recurrent Pericarditis
- Interventions
- Not listed
- Lead sponsor
- Kiniksa Pharmaceuticals International, plc
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 29
- States / cities
- Anchorage, Alaska • Tucson, Arizona • La Jolla, California + 23 more
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Interventions
- Mavrilimumab, Placebo
- Drug
- Lead sponsor
- Kristin Hudock
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Prurigo Nodularis, Pruritis
- Interventions
- Vixarelimab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- COVID
- Interventions
- mavrilimumab, Placebo
- Drug · Other
- Lead sponsor
- Kiniksa Pharmaceuticals International, plc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 814 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • Chicago, Illinois + 6 more
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
- Interventions
- KPL-716, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
- Conditions
- Recurrent Pericarditis
- Interventions
- KPL-914
- Drug
- Lead sponsor
- Kiniksa Pharmaceuticals (UK), Ltd.
- Industry
- Eligibility
- 6 Years to 75 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more